Cargando…

Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites

The intestinal microbiome and bacterial translocation (BT), the passage of microorganisms from the gut lumen to mesenteric lymph nodes and other extra‐intestinal sites, are main mechanisms implicated in liver injury and further decompensation in patients with cirrhosis. We hypothesized that obeticho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Kathleen, Hung, Adelina, Parmer, Caitlin, Yang, Hui, Jain, Dhanpat, Lim, Bentley, Goodman, Andrew L., Garcia‐Tsao, Guadalupe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435275/ https://www.ncbi.nlm.nih.gov/pubmed/34510838 http://dx.doi.org/10.1002/hep4.1740

Ejemplares similares

Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
por: Edwards, JE, et al.
Publicado: (2016)

Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
por: John, Binu V., et al.
Publicado: (2021)

Ascites and Cirrhosis
por: Stott, Hugh
Publicado: (1911)

Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis
por: Roda, A, et al.
Publicado: (2017)

Ascites, refractory ascites and hyponatremia in cirrhosis
por: Fortune, Brett, et al.
Publicado: (2017)

Intestinal Lymphangiectasia Associated With Refractory Ascites in a Cirrhosis Patient
por: Kumar, Ramesh, et al.
Publicado: (2021)

Operation for the Ascites of Cirrhosis
Publicado: (1899)

Ascites in Cirrhosis of the Liver
Publicado: (1905)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

Guidelines on the management of ascites in cirrhosis
por: Aithal, Guruprasad P, et al.
Publicado: (2021)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

An evaluation of ascitic calprotectin for diagnosis of ascitic fluid infection in children with cirrhosis
por: Honar, Naser, et al.
Publicado: (2022)

Ascites in Early Alcoholic Cirrhosis of the Liver
por: Weber, F. Parkes
Publicado: (1903)

Management of Ascites in Patients with Cirrhosis: An Update
por: Zaccherini, Giacomo, et al.
Publicado: (2021)

Operative Treatment of Ascites in Cirrhosis of the Liver
Publicado: (1909)

Innovative approaches to the management of ascites in cirrhosis
por: Wong, Florence
Publicado: (2023)

Tense Ascites in Cirrhosis: Paracentesis With Albumin Infusion Versus Spontaneous Ascites Filtration
por: Robson, Simon C.
Publicado: (1994)

Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis
por: Stirnimann, G., et al.
Publicado: (2017)

Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature
por: Hvas, Christian Lodberg, et al.
Publicado: (2018)

Management of Renal Failure and Ascites in Patients with Cirrhosis
por: Madan, Kaushal, et al.
Publicado: (2011)

Current management of refractory ascites in patients with cirrhosis
por: Zhao, Ruihong, et al.
Publicado: (2017)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

Aggressive nutrition intervention reduces ascites and frequency of paracentesis in malnourished patients with cirrhosis and ascites
por: Vidot, Helen, et al.
Publicado: (2017)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
por: Liu, Szu-Yu, et al.
Publicado: (2022)

Prevalence of spontaneous bacterial peritonitis in liver cirrhosis with ascites
por: Oladimeji, Ajayi Akande, et al.
Publicado: (2013)

Management of refractory ascites in cirrhosis: Are we out of date?
por: Annamalai, Alagappan, et al.
Publicado: (2016)

Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites
por: Thaler, Johannes, et al.
Publicado: (2021)

An Unusual Cause of Ascites in Liver Cirrhosis: Peritoneal Tuberculosis
por: Mann, Rupinder, et al.
Publicado: (2021)

Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascites
por: Ripoll, Cristina, et al.
Publicado: (2022)

Haemorrhagic versus non haemorrhagic ascites in cirrhosis: Their relationship and impact on prognosis of liver cirrhosis
por: Naqvi, Iftikhar Haider, et al.
Publicado: (2020)

Classification of Cirrhosis: The Clinical Use of HVPG Measurements
por: Albilllos, Agustín, et al.
Publicado: (2011)

The Content of Dipeptidases and Acid Proteinases in the Ascitic Fluid of Mice with Ascites Tumours
por: Sylvén, B., et al.
Publicado: (1959)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bqfsfgu6flj1atec9u9gj3sts0